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Purpose or Objective: Stereotactic ablative radiotherapy 
(SABR) for liver metastases is currently accepted as a 
standard treatment option for patients with liver metastases. 
Multiple studies have demonstrated high rates of local control 
and low risk of serious toxicities. However, there is limited 
prospective patient-reported health-related quality of life 
data (HRQoL). Herein, we report the acute HRQoL changes in 
patients treated with SABR for liver metastases. 
 
Material and Methods: A prospective study was performed to 
measure HRQoL changes in patients treated with SABR to 1-3 
hepatic metastases. Doses of 30- 60 Gy in 3-5 fractions were 
delivered as per institutional policy depending on tumor 
location, histology and size. Changes in patients’ self-
reported HRQoL were measured using the European 
Organisation for Research and Treatment of Cancer (EORTC) 
Quality of Life Questionnaire–Core 15 Palliative (C15) at 
baseline (T0) and first follow-up (T1: 6 - 8 weeks post-SABR). 
The C15 consists of 15 questions; 2 multi-item symptom 
scales along with 5 single item symptom scales and a final 
overall QoL question. A significant change in HRQoL was 
defined as [T0 score-T1 score] > 0.5SD, where SD was the 
standard deviation of baseline values for each scale. For the 
overall QoL question, a significant change was defined by a 
10-point or greater change from baseline. 
 
Results: Fifty patients were included. Median age at 
treatment was 65 (40-88) years. Median BED10 was 98 Gy. 
The 4 most common primary sites of cancer were: gastro-
intestinal (29), breast (9), renal cell (4) and lung (4). All 
patients were Child-Pugh score A. Nine patients had previous 
hepatectomies for liver metastases. Thirty-one patients had 
oligometastatic disease (≤5 metastases)  and 19 had 
oligoprogression (≤5 metastases progressing). Forty -seven 
patients filled the C15 at T1 (94%). The majority of patients 
did not report a significant change in any of the C15 scales 
(table 1). For the overall QoL, 64% of the patients reported 
no significant change at T1, 24% had deterioration and 13% 




Conclusion: SABR offers a non-invasive option for liver 
metastases ablation. Acute patient-reported outcomes, as 
measured by C-15, for patients with liver metastases treated 
with SABR seem favourable. Longer follow-up is needed. 
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Purpose or Objective: Treating locally advanced pancreatic 
cancer (LAPC) remains a challenging issue. Chemotherapy or 
chemoradiotherapy alone have not demonstrated their 
efficacy. A strategy combining chemotherapy and 
chemoradiotherapy seems promising. Our retrospective 
analysis aims to evaluate effectiveness and tolerability of 
induction chemotherapy with Folfirinox followed by 
chemoradiotherapy in patients with LAPC. 
 
Material and Methods: Nineteen patients treated for LAPC 
between Mars 2010 and February 2015 were retrospectively 
identified. These patients with unresectable disease, were 
initially treated with Folfirinox and then received a 
chemoradiotherapy with capecitabine or gemcitabine in case 
of stable disease. Survival was estimated with Kaplan Meier 
method. 
 
Results: Median number of cycles achieved for Folfirinox was 
5. Following chemotherapy, all patients had stable disease 
and received chemoradiotherapy with capecitabine (53%) or 
gemcitabine (47%). Majority of patients (63%) received 
radiotherapy at a dose of 50.4 Gray in 28 fractions. Toxicities 
are acceptable: three cases of grade 3 nausea / vomiting, 
three cases of grade 3 asthenia and three cases of grade 3 
diarrhea were described during chemotherapy. No grade 3 
toxicity was identified during chemoradiotherapy. The 
median follow-up time was 9 months (1-43 months). Survival 
rates were 93.8% at six months, 52.7% at 1 year and 21.1% at 
2 years. Disease free survival rates were 35.3% at six months, 
7.8% at 1 year and 0% at 2 years. Local recurrence free 
survival rates were 75.3% at six months, 47.3% at 1 year and 
31.6 at 2 years. Distant recurrence free survival rates were 
34.3% at six months, 18.3% at 1 year and 9.2% at 2 years. At 
the end of the therapeutic procedure, one patient received 
surgical resection. 
 
Conclusion: Induction chemotherapy with Folfirinox followed 
by chemoradiotherapy in locally advanced pancreatic 
adenocarcinoma seems effective and allows very promising 
overall and progression free survival rates. Larger studies 
would be needed to conclusively confirm these observations. 
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Purpose or Objective: Gastrointestinal (GI) toxicity impedes 
dose escalation in radiotherapy for pancreatic cancer and 
limits local tumour control. Clinical data on tolerance doses 
for the organs of the proximal digestive system remain 
sparse. We analysed patterns of toxicity in patients treated 
with concomitant chemoradiotherapy (gemcitabine and 
cisplatin) with nelfinavir (hypoxia modifier) to identify 
associated dosimetric factors and establish predictive cut-off 
values to inform radiotherapy planning. 
 
Material and Methods: Dose-volumes and acute toxicity data 
were analysed for 21 patients treated for locally-advanced 
pancreatic cancer in a prospective phase II clinical trial 
(ARCII, EudraCT 2008-006302-42). Radiotherapy comprised 
50.4Gy in 28 daily fractions to the tumour and elective lymph 
nodes followed by a sequential boost to the primary tumour 
of 9Gy in 5#. Univariate analysis was performed to 
investigate association of the dose-volume received by 
stomach and duodenum with RTOG upper GI toxicity 
symptoms, and of small-bowel with diarrhoea. Receiver 
Operating Characteristic analysis was used to identify 
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strongest predictive factors and to derive optimum cut-off 
values for predicting likelihood of toxicity incidence. 
 
Results: Grade ≥2 acute RTOG upper GI toxicity attributed to 
treatment was seen in 11 patients (52%), grade ≥3 in 3 (14%); 
grade ≥2 diarrhoea was recorded in 3 patients (14%), grade ≥3 
in 2 (10%). In patients who experienced grade ≥2 toxicity, 
stomach V15-55 Gy (absolute volume of stomach receiving 
15-55 Gy, in cm3) were significantly larger when compared to 
those without (p<0.05, Mann-Whitney). Differences in V35 Gy 
and V40 Gy remained significant after Bonferroni correction 
(p<0.004) and ROC analysis was performed to identify the 
most predictive cut-off values: V35 Gy 55.7cm3 and V40 Gy 
43.6 cm3 (both sensitivity 0.82, specificity 0.80, Youden 
index = 0.62). Significant associations were not seen between 
duodenal dose-volume and acute toxicity, nor between small-





Conclusion: In concomitant chemoradiotherapy with 
nelfinavir for pancreatic cancer, stomach dosimetric 
parameters were associated with clinically important acute 
radiotherapy toxicity and thresholds were derived for 
predicting toxicity risk. Stomach V35 Gy and V40 Gy were 
most strongly predictive of acute grade ≥2 side effects. 
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Purpose or Objective: Tolerance of small bowel is the dose 
limiting factor in radiation therapy for abdominal neoplasms. 
Bowel constraints for treatment planning in abdominal 
radiotherapy derive from scientific publications of pelvic 
tumors. This study has the aim to evaluate dose tolerance of 
small bowel detecting acute toxicities in patients with 
pancreatic cancer treated with radiochemotherapy. 
 
Material and Methods: Patients with pancreatic cancer were 
treated between 2009 and 2014 with 3D-conformal 
radiotherapy with a total dose of 5040 cGy and conventional 
fractionation. Chemotherapy with gemcitabine or 
fluoropyrimidine was simultaneously administered. Nausea, 
vomit and loss of weight, as acute upper gastrointestinal (GI) 
toxicities, were scheduled using RTOG scale. In all patients 
small bowel loops and bowel sac were contoured using 
QUANTEC guidelines and DVHs were analyzed for this 
structures using R statistical software (http://www.R-
project.org). 
 
Results: Forty-three patients with a median age of 66 years 
(range 42-79), 14 resected and 29 unresected, were 
analyzed. Fourteen (32%) patients reported no upper GI 
toxicity; on 8 (19%), 12 (28%) and 9 (21%) patients were 
observed respectively grade 1, 2 and 3 toxicity. No grade 4 
toxicity was recorded. Nineteen patients discontinued 
radiotherapy but all of them completed the treatment. 
Analyzing V Dose on DVHs by logistic regression, small bowel 
loops V36 Gy resulted as the parameter which most 
influenced upper GI G1 or higher Toxicity (p<0.05). 
Multivariate analysis showed no impact of surgery on upper GI 
toxicity. 
 
Conclusion: Our preliminary analysis suggests that new 
constraints for radiochemotherapy in upper GI cancer could 
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Purpose or Objective: Specific results of SBRT for liver 
metastases from rare tumors have been reported scarcely. 
This applies also to metastases from low grade 
neuroendocrine tumors (NET), either derived from 
gastrointestinal organs or from an unknown primary site. 
Here we report two cases of multiple liver metastases from 
low grade NET repeatedly treated by means of SBRT, 
achieving the outcome of long-term local control. 
 
Material and Methods: From March 2011 to September 2015 
49 SBRT courses were delivered to 39 patients for liver 
metastases from different primaries. All courses were given 
by VMAT with 6 MV photons, image guided by CBCT in every 
fraction. Since 2013, deep inspiration breath hold was 
adopted in order to control organ motion. Two patient had 
metastases from well differentiated neuroendocrine tumors, 
one from an unknown primary (patient A), the other from a 
pancreatic primary (patient B). Patient A underwent two 
SBRT courses, both in 2011, the first one on segment 6 (CTV 
volume 25 ml, CTV dose 75 Gy, PTV 50 Gy, in 3 fractions), 
the second one on two adjacent metastases, respectively in 
segment 7 and 8 (total CTV volume 54 ml, CTV dose 60 Gy, 
PTV 50 Gy, in 3 fractions).Patient B received three courses, 
respectively in 2013, 2014 and 2015. The first SBRT was 
delivered on segment 6 (CTV volume 38 ml, CTV dose 50 Gy, 
PTvV45 Gy, in 5 fractions), the second on segment 8 (CTV 
volume 30 ml, CTV dose 50 Gy, PTV 45 Gy, in 5 fractions), 
the last on segment 4 (CTV volume 44 ml, CTV dose 50 Gy, 
PTV 45 Gy, in 5 fractions ). Patient A was found to be 
somatostatine receptor-negative, thus he was followed up 
mainly by serial CT scans; also, his disease status matched 
well to trends of two biomarkers (chromogranin A and 
gastrin). Patient B was followed up by alternating CT scans 
and PET/CT-68Ga-DOTATOC. 
 
Results: At last follow up patient A achieved long-term local 
control in S6 metastasis (45 months) as well as in S7-8 (42 
months), while showing disease progression at a new liver 
site at 45 months after first SBRT. At last follow up patient B 
achieved local control in all sites (S6: 30 months; S8: 13 
months; S4: 6 months) with a durable partial PET response in 
S8 and S4 and a complete PET response in S6. Disease 
progression took place in two bone sites at 30 months after 
first SBRT, without any concomitant liver progression. 
 
